Laure Escoubet, Ph.D., is the Chief Scientific Officer of Light Horse Therapeutics. She joined the company in January 2023, bringing her leadership skills to bear with the recruitment of a highly performing drug discovery team and the successful launch of Light Horse’s gene editing and chemoproteomics platforms.
Laure brings 20 years of experience in building successful drug discovery teams, leading strategic collaborations and driving drug discovery programs into the clinic. She previously served as Vice President of Biology at Zentalis Pharmaceuticals, and as Head of Epigenetic Drug Discovery at Celgene/Bristol-Myers Squibb, in addition of holding other leadership roles in early drug discovery in Oncology.
Laure has been involved in the development of small molecules, antibodies and Antibody-Drug Conjugates in Oncology and she has contributed her epigenetic expertise to other therapeutic areas including Inflammation and Neuroscience.
Laure completed her postdoctoral training in gene regulation at the University of California, San Diego, in the laboratory of Dr. Christopher K. Glass and earned her PhD in Human Pathophysiology from the University Paul Sabatier in Toulouse, France.